NEW YORK–(BUSINESS WIRE)– #AIPrecisionMedicine–Ataraxis AI, a company building clinical AI tools to personalize cancer care, announced today that it will present nine studies at the 2026 San Antonio Breast Cancer Symposium (SABCS), including several oral presentations. The research validates Ataraxis AI for prognosis and chemotherapy benefit prediction in the landmark Phase III TAILORx and SWOG-8814 trials and in multi-national real-world cohorts, with head-to-head comparisons against legacy genomic assays. Ataraxi

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.